Dr. Amro M. Stino

Dr. Feldman is the director of the NeuroNetwork for Emerging Therapies at Michigan Medicine and the ALS Center of Excellence at Michigan Medicine. The latter includes the Pranger ALS Clinic, one of the top multidisciplinary clinics caring for those suffering from amyotrophic lateral sclerosis (ALS). She serves as the University of Michigan James W. Albers Distinguished University Professor and the Russell N. DeJong Professor of Neurology at Michigan Medicine. Dr. Feldman is one of the world’s leading authorities on neurodegenerative disease.Dr. Feldman is a compassionate and dedicated physician who cares deeply about her patients. She has been recognized for her clinical excellence by numerous organizations and is annually named as one of the “Best Doctors in America.” Her forward-thinking, collaborative, multidisciplinary approach has transformed how neurodegenerative diseases are diagnosed, treated, and prevented.Dr. Feldman has made significant contributions to biomedical research and clinical care in many critical areas of neurodegenerative disease. She has authored over 530 peer-reviewed publications, 74 book chapters, and 5 books on the pathology, diagnosis, and treatment of neurological diseases. Dr. Feldman has been continuously funded by the NIH since 1989 and is currently the principal or co-investigator of numerous clinical trials and grants. She has received numerous awards and honors throughout her remarkable career, including the University of Michigan’s Early Distinguished Career Award, the Distinguished Faculty Achievement Award, and the Distinguished Alumnus Achievement Award. She was also the first woman in 25 years to receive the Robert S. Schwab Award from the American Clinical Neurophysiology Society. In 2022, Dr. Feldman was awarded the University of Michigan Distinguished Professorship, the highest faculty honor at University of Michigan.Dr. Feldman is actively committed to and involved in professional service. She served as President of the Peripheral Nerve Society from 2007-2009 and President of the American Neurological Association (ANA) from 2011-2013. Dr. Feldman is an elected member of the National Academy of Medicine (NAM) and Association of American Physicians, and a Fellow of the American Association for the Advancement of Science. Dr. Feldman is the Editor of the Contemporary Neurology Series and also serves on a number of editorial boards for leading scientific journals, including The Lancet Neurology, Nature Reviews Neurology, JAMA Neurology and Journal of Neurology, Neurosurgery and Psychiatry. Dr. Feldman is highly rated in 33 conditions, according to our data. Her clinical expertise encompasses Peripheral Neuropathy, Diabetic Neuropathy, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), and Autonomic Neuropathy. Dr. Feldman is board certified in Neurology and Electrodiagnostic Medicine.

Stephen Goutman, MD, MS is an Associate Professor in the Department of Neurology and Director of the Amyotrophic Lateral Sclerosis Clinic and ALS Center of Excellence at Michigan Medicine. After obtaining a degree in neuroscience at the Johns Hopkins University (Baltimore, MD), Dr. Goutman completed his medical degree at the University of Chicago Pritzker School of Medicine (Chicago, IL) and his neurology residency and neuromuscular fellowship at Cleveland Clinic (Cleveland, OH). He received a Master’s in Clinical Research Design and Statistical Analysis at the University of Michigan (Ann Arbor, MI).Dr. Goutman evaluates and treats patients with neuromuscular diseases and is interested in diseases such as myasthenia gravis and muscle diseases. His area of expertise is amyotrophic lateral sclerosis (ALS)/Lou Gehrig’s Disease where his focus is delivering comprehensive and compassionate care. He is Director of the ALS Clinic, an ALS Association Certified Center of Excellence (http://www.umich-als.org/), where he leads a team of providers that care for persons with ALS and their families. Dr. Goutman is inspired by his patients and thus aims to provide the highest level of care.Dr. Goutman’s research is focused on identifying causes of and treatments for ALS. He leads research efforts that received funding by the National Institutes of Health and the Centers for Disease Control aimed at identifying environmental risk factors and causes of ALS (https://umhealthresearch.org/#studies/HUM00028826) and showed, in an article that received widespread attention, a connection between ALS and organochlorine pesticides (https://jamanetwork.com/journals/jamaneurology/fullarticle/2519875). Dr. Goutman also helps direct the University of Michigan ALS Biorepository which provides essential resources to ALS researchers within and external to the University of Michigan enabling studies into areas of ALS genetics, epigenetics, and immunology.Dr. Goutman is a site principal investigator of several multisite clinical trials focused on identifying new ALS treatments and causes and is an active participant with the Northeast ALS Consortium (NEALS) to improve care for ALS. He received a 2016 Young Investigator Award by the World Federation of Neurology Research Group on Motor Neuron Diseases. Dr. Goutman is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Spinal Muscular Atrophy (SMA), and Spinal and Bulbar Muscular Atrophy. Dr. Goutman is board certified in Neurology, Neuromuscular Medicine, and Electrodiagnostic Medicine.

Henry L. Paulson, M.D., Ph.D., is the Lucile Groff Professor of Neurology for Alzheimer's Disease and Related Disorders in the Department of Neurology at the University of Michigan. Dr. Paulson joined the U-M faculty in 2007, and he currently directs the Michigan Alzheimer’s Disease Center (MADC) and co-direct the U-M Protein Folding Diseases Initiative.Dr. Paulson received his medical degree and doctorate in Cell Biology from Yale University in 1990. He then completed a neurology residency and neurogenetics/movement disorders fellowships at the University of Pennsylvania. In 1997, he joined the Neurology faculty at the University of Iowa, where he remained until 2007.Dr. Paulson's research and clinical interests concern the causes and treatment of age-related neurodegenerative diseases, with an emphasis on polyglutamine diseases, Alzheimer's disease and frontotemporal dementia. In 1997, his lab described abnormal protein aggregates in the polyglutamine diseases, which now are recognized as a pathological hallmark in this important class of inherited diseases. Using test tube, cell-based and animal models, he has contributed to advances in the understanding of various neurodegenerative diseases. His lab also has helped pioneer the use of gene silencing methods as potential therapy for the many neurological disorders caused by toxic mutant genes.Nationally, Dr. Paulson has directed popular courses at the American Academy of Neurology meetings, serves on the scientific advisory boards of numerous disease-related national organizations, and is past Chair of the Board of Scientific Counselors at the National Institute for Neurological Disorders and Stroke at the National Institutes of Health.Among his awards, Dr. Paulson is an Ellison Medical Foundation New Scholar in Aging, a semifinalist for the W.M. Keck Foundation Young Scholars in Medical Research, and a recipient of the Paul Beeson Physician Faculty Scholar in Aging Award from the American Federation for Aging Research. Dr. Paulson is highly rated in 41 conditions, according to our data. His clinical expertise encompasses Spinocerebellar Ataxia Type 3, Olivopontocerebellar Atrophy, Spinocerebellar Ataxia, and Drug Induced Dyskinesia. Dr. Paulson is board certified in Neurology.